secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2021-07-29T23:59:59+00:00
Accession:  0001384101-21-000138
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q2 revenue $55.1M (+166% YoY); raises 2021 guidance to $200-208M
-------------------------------------------------------------------------

- Total revenue $55.1M, up 166% YoY; net loss $9.0M ($0.13 per share) improved 18%.
- Genomic test volume 20,856, up 215% YoY and 44% sequentially.
- Raises FY2021 revenue guidance to $200-208M from $190-200M.
- Received Medicare coverage for Decipher Bladder; signed managed care contract for Decipher Prostate (~20M members).
- Planned HalioDx acquisition announced; new CFO, CBO, CIO appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410121000138/0001384101-21-000138-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410121000138/vcyt-20210729.htm
  HTML page:      https://secwatch.observer/filing/0001384101-21-000138

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer